Drug Updates

Updates for Bristol Myers Squibb's ISTODAX® for injection, for intravenous use The CMS 2021 ASP Drug Pricing Files for the 4th quarter effective October 1, 2021 through December 31, 2021 reflects updates for ISTODAX® (romidepsin) for injection, for intravenous use.  The update includes the following changes which are effective October 1, 2021: [...]

New Report Finds Biosimilars Could Save States Billions of Dollars Annually Interactive Tool Shows State-by-State Cost-Saving Potential of Biosimilars The Biosimilars Forum, in partnership with the Pacific Research Institute (PRI), released a report and interactive tool highlighting the billions of dollars that biosimilars can save states. READ MORE

Update: A New Indication for Genentech's TECENTRIQ (atezolizumab) Genentech is excited to share the news of the Food and Drug Administration (FDA) approval of TECENTRIQ® (atezolizumab) as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with stage II-IIIA non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression on [...]

Oncologists Warn Congress Cancer Care is Held Hostage by Build Back Better Drug Pricing Provisions The Community Oncology Alliance (COA), a national non-profit representing independent oncology practices and the patients they serve, is warning Congress that the way drug pricing provisions in the current draft of the Build Back Better (BBB) [...]

Updated Healthcare Common Procedure Coding System Code (HCPCS) and dose descriptor for Amgen’s Neulasta® (pegfilgrastim) Onpro® and Neulasta® Neulasta® (pegfilgrastim) Onpro® and Neulasta® have an updated Healthcare Common Procedure Coding System (HCPCS) Code and dose descriptor, effective January 1, 2022. The UPDATED HCPCS CODE is J2506 The UPDATED DOSE DESCRIPTOR is Injection, [...]